Eisai (4523 JT) and Biogen (BIIB) announced Eisai and Biogen announce biologics licence application for subcutaneous formulation of LEQEMBI for treating early Alzheimer's disease was accepted in China
SourceNewswires
Importance
Level 1
#BIOGEN IDEC INC#BIIB.US#EISAI CO LTD#4523.JT#EQUITIES#ASIAN SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#ASIAN EQUITIES